SecurityCNSX:GHG / Global Hemp Group Inc
IndustryCannabis and Medical Marijuana Dispensaries
Institutional Owners0

Institutional Stock Ownership and Shareholders

Global Hemp Group Inc (CNSX:GHG) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Global Hemp Group Inc (CNSX:GHG) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related News Stories

Your Daily Pharma Scoop: Audentes's New Designation, Esmya Rejected, Agilent Approved

2018-08-23 seekingalpha
Discussions: Audentes Therapeutics' (BOLD) AT132 receives FDA designation of a Regenerative Medicine Advanced Therapy (‘RMAT). The therapy is indicated for treatment of X-linked myotubular myopathy (‘XLMTM). RMAT is in many ways similar to the Breakthrough Therapy status and allows accelerated review of a drug along with more frequent interaction with the FDA during the development stage. The therapy has already acquired Rare Pediatric disease, Fast track and Orphan Drug Designation in the U. (24-1)